GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Agilent Technologies Inc (NYSE:A) » Definitions » Ending Cash Position

Agilent Technologies (Agilent Technologies) Ending Cash Position : $1,750 Mil (As of Jan. 2024)


View and export this data going back to 1999. Start your Free Trial

What is Agilent Technologies Ending Cash Position?

Agilent Technologies's Ending Cash Position for the quarter that ended in Jan. 2024 was $1,750 Mil.

Agilent Technologies's quarterly Ending Cash Position increased from Jul. 2023 ($1,332 Mil) to Oct. 2023 ($1,593 Mil) and increased from Oct. 2023 ($1,593 Mil) to Jan. 2024 ($1,750 Mil).

Agilent Technologies's annual Ending Cash Position declined from Oct. 2021 ($1,490 Mil) to Oct. 2022 ($1,056 Mil) but then increased from Oct. 2022 ($1,056 Mil) to Oct. 2023 ($1,593 Mil).

Agilent Technologies Ending Cash Position Historical Data

The historical data trend for Agilent Technologies's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Agilent Technologies Ending Cash Position Chart

Agilent Technologies Annual Data
Trend Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,388.00 1,447.00 1,490.00 1,056.00 1,593.00

Agilent Technologies Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,253.00 1,178.00 1,332.00 1,593.00 1,750.00

Agilent Technologies Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Agilent Technologies's Ending Cash Position for the fiscal year that ended in Oct. 2023 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=1056+537
=1,593

Agilent Technologies's Ending Cash Position for the quarter that ended in Jan. 2024 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=1593+157
=1,750

Agilent Technologies Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Agilent Technologies's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Agilent Technologies (Agilent Technologies) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Agilent Technologies Inc (NYSE:A) » Definitions » Ending Cash Position
Comparable Companies
IDXX IQV MTD ICLR ILMN WAT LH DGX CRL RVTY TSE:2309 TMO DHR XSWX:LONN SHSE:603259 XPAR:BIM EXAS MEDP XPAR:ERF NTRA
Traded in Other Exchanges
A:Mexico 1A:Italy AG8:Germany AG8:Germany
Address
5301 Stevens Creek Boulevard, Santa Clara, CA, USA, 95051
Website
https://www.agilent.com
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools, cross lab (consisting of consumables and services related to life science and applied tools), and diagnostics and genomics. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. and China representing the largest country concentrations.
Executives
Philip Binns officer: Senior Vice President 5301 STEVENS CREEK BLVD., SANTA CLARA CA 95051
Rodney Gonsalves officer: V.P., Corporate Controller 5301 STEVENS CREEK BLVD., SANTA CLARA CA 95051
Henrik Ancher-jensen officer: Sr. Vice President 5301 STEVENS CREEK BLVD., SANTA CLARA CA 95051
Michael R. Mcmullen officer: CEO and President 5301 STEVENS CREEK BLVD., MS 1A-LC, SANTA CLARA CA 95051
George A Scangos director C/O EXELIXIS INC, 170 HARBOR WAY, SAN FRANCISCO CA 94083
Otis W Brawley director 5203 BRISTOL INDUSTRIAL WAY, BUFORD GA 30518
Mikael Dolsten director 5 GIRALDA FARMS, MADISON NJ 07940
Mala Anand director C/O COTIVITI HOLDINGS, INC., 115 PERIMETER CENTER PLACE, SUITE 700, ATLANTA GA 30346
Sue H. Rataj director C/O CABOT CORPORATION, TWO SEAPORT LANE, SUITE 1300, BOSTON MA 02210
Dow R Wilson director VARIAN MEDICAL SYSTEMS INC, 3100 HANSEN WAY MAIL STOP E327, PALO ALTO CA 94304
Boon Hwee Koh director C/O AGILENT TECHNOLOGIES, 5301 STEVENS CREEK BLVD, MS 1A-LC, SANTA CLARA CA 95051
Heidi Fields director 5301 STEVENS CREEK BLVD, MS 1A-LC, SANTA CLARA CA 95051
Hans Edgar Bishop director 60 WEST 66TH STREET, 26A, NEW YORK NY 10023
Daniel K Podolsky director 5301 STEVENS CREEK BLVD., SANTA CLARA CA 95051
Padraig Mcdonnell officer: Senior Vice President 5301 STEVENS CREEK BLVD, SANTA CLARA CA 95051